Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

161. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Full Text available with Trip Pro

Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Clomiphene citrate (CC) is generally considered first-line treatment in women with anovulation due to polycystic ovary syndrome (PCOS). Ovulation induction with follicle-stimulating hormone (FSH; gonadotrophins) is second-line treatment for women who do not ovulate or conceive while taking CC. Metformin may increase (...) the effectiveness of ovulation induction with gonadotrophins and may promote safety by preventing multiple pregnancy.To determine the effectiveness and safety of metformin co-treatment during ovulation induction with gonadotrophins with respect to rates of live birth and multiple pregnancy in women with PCOS.We searched the Cochrane Gynaecology and Fertility (CGF) Group specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and the Cumulative Index

2017 Cochrane

162. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Full Text available with Trip Pro

Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Recent changes to the U.S. Food and Drug Administration boxed warning for metformin will increase its use in persons with historical contraindications or precautions. Prescribers must understand the clinical outcomes of metformin use in these populations.To synthesize data addressing outcomes of metformin use in populations with type 2 diabetes (...) diabetes regimens that included metformin with those that did not; and 3) reported all-cause mortality, major adverse cardiovascular events, and other outcomes of interest.2 reviewers abstracted data and independently rated study quality and strength of evidence.On the basis of quantitative and qualitative syntheses involving 17 observational studies, metformin use is associated with reduced all-cause mortality in patients with CKD, CHF, or CLD with hepatic impairment, and with fewer heart failure

2017 Annals of Internal Medicine

163. Metformin Use in Patients With Historical Contraindications Full Text available with Trip Pro

Metformin Use in Patients With Historical Contraindications 28055052 2017 12 08 2018 12 02 1539-3704 166 3 2017 02 07 Annals of internal medicine Ann. Intern. Med. Metformin Use in Patients With Historical Contraindications. 225-226 10.7326/M16-2712 Lipska Kasia J KJ From Yale School of Medicine, New Haven, Connecticut. eng K23 AG048359 AG NIA NIH HHS United States L30 AG045923 AG NIA NIH HHS United States P30 AG021342 AG NIA NIH HHS United States Journal Article Research Support, N.I.H (...) ., Extramural Comment 2017 01 03 United States Ann Intern Med 0372351 0003-4819 0 Hypoglycemic Agents 9100L32L2N Metformin AIM IM Ann Intern Med. 2017 Feb 7;166(3):191-200 28055049 Contraindications Diabetes Mellitus, Type 2 Humans Hypoglycemic Agents Metformin 2017 1 6 6 0 2017 12 9 6 0 2017 1 6 6 0 ppublish 28055052 2595890 10.7326/M16-2712 PMC5334793 NIHMS850043 N Engl J Med. 1998 Jan 22;338(4):265-6 9441244 Ann Intern Med. 2011 May 3;154(9):602-13 21403054 Lancet. 1998 Sep 12;352(9131):854-65 9742977

2017 Annals of Internal Medicine

164. Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V

Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Saxagliptin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-33 Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-33 Version 1.0 Saxagliptin/metformin (type 2 diabetes mellitus) 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

165. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.

Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving (...) of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017 Sep;108(3):426-41. [80 references] This is the current release of the guideline. This guideline meets NGC's 2013 (revised) inclusion criteria. Age Group UMLS Concepts ICD9CM (628.9), (256.4) MSH

2017 National Guideline Clearinghouse (partial archive)

166. Role of metformin for ovulation induction in infertile patients with PCOS

Role of metformin for ovulation induction in infertile patients with PCOS Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Metforminalonecomparedwithplaceboincreasestheovulationrateinwomenwithpolycysticovarysyndrome(PCOS)butshouldnot be used as?rst-line therapy for anovulation because oral ovulation (...) induction agents such as clomiphene citrate or letrozole alone are muchmoreeffectiveinincreasingovulation,pregnancy,andlive-birthratesinwomenwithPCOS.Thereisfairevidencethatmetformin alone does not increase rates of miscarriage when stopped at the initiation of pregnancy and insuf?cient evidence that metformin in combinationwithotheragentsusedtoinduceovulationincreaseslive-birthrates.(FertilSteril 2017;108:426–41.2017byAmerican Society for Reproductive Medicine.) Discuss: You can discuss this article

2017 Society for Assisted Reproductive Technology

167. Role of metformin in overweight and obesity people without diabetes: a systematic review and network meta-analysis

Role of metformin in overweight and obesity people without diabetes: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

168. The association between oral contraceptive and Metformin, dyslipidemia and hormone in women with polycystic ovary syndrome: a systematic review and meta-analysis

The association between oral contraceptive and Metformin, dyslipidemia and hormone in women with polycystic ovary syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2017 PROSPERO

169. Genetic polymorphisms of Organic Cation Transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review

Genetic polymorphisms of Organic Cation Transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2017 PROSPERO

170. Metformin and sulphonylurea (second- or third-generation) combination therapy for adults with type 2 diabetes mellitus [Cochrane protocol]

Metformin and sulphonylurea (second- or third-generation) combination therapy for adults with type 2 diabetes mellitus [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

171. Metformin and sulphonylurea (second- or third-generation) combination therapy for adults with type 2 diabetes mellitus [Cochrane Protocol]

Metformin and sulphonylurea (second- or third-generation) combination therapy for adults with type 2 diabetes mellitus [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

172. Is the use of metformin in patients on renal dialysis hazardous for life?

Is the use of metformin in patients on renal dialysis hazardous for life? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

173. The use of metformin and ovarian cancer survival

The use of metformin and ovarian cancer survival Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect

2017 PROSPERO

174. The role of metformin in the treatment of thyroid nodules with insulin resistance: a systematic review and meta-analysis

The role of metformin in the treatment of thyroid nodules with insulin resistance: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

175. Meta-analysis of body weight changes after metformin intake in the elderly

Meta-analysis of body weight changes after metformin intake in the elderly Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

176. Association of metformin with breast cancer incidence and mortality: a systematic review and meta-analysis

Association of metformin with breast cancer incidence and mortality: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2017 PROSPERO

177. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions 4 Department of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Metformin Use in Patients with Contraindications or Precautions September 2016 Prepared for: Department of Veterans Affairs Veterans Health Administration Quality Enhancement Research Initiative Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence-based Synthesis Program (...) Affairs and should not be distributed outside the agency. Metformin Use in Patients with Contraindications or Precautions Evidence-based Synthesis Program i PREFACE The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for four ESP Centers, and each Center has

2017 Veterans Affairs Evidence-based Synthesis Program Reports

179. Does metformin prevent hypertensive disorders of pregnancy: a systematic review and meta-analysis?

Does metformin prevent hypertensive disorders of pregnancy: a systematic review and meta-analysis? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

180. Effectivness of liraglutide alone or in combination with metformin in treatment of obese PCOS: systematic review and meta-analysis

Effectivness of liraglutide alone or in combination with metformin in treatment of obese PCOS: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO